Finally, we investigated whether the GPR-TME signatures could predict the response to immunotherapy in BLCA patients, and the response to immunotherapy differed among risk groups in this model, with lower GPR signatures or higher TME signatures implying better levels of immune response. This evidence concerns the gene ALDH18A1 and bladder transitional cell carcinoma.